AbioCor

Last updated

AbioCor was a total artificial heart (TAH) developed by the Massachusetts-based company AbioMed. It was fully implantable within a patient, due to a combination of advances in miniaturization, biosensors, plastics and energy transfer. The AbioCor ran on a rechargeable source of power. The internal battery was charged by a transcutaneous energy transmission (TET) system, meaning that no wires or tubes penetrated the skin, reducing the risk of infection. However, because of its size, this heart was only compatible with men who had a large frame. It had a product life expectancy of 18 months. [1] [2] [3] [4] [5]

Contents

AbioCor was surgically introduced into 15 total patients, 14 of them during a clinical trial and one after FDA approval. However, due to insufficient evidence of its efficacy, AbioMed abandoned further development of the product. [6] [7] [8]

History

AbioMed was founded by Param Singh and David Lederman. The company began development of the AbioCor device in the 1990s, beginning animal studies in 1998 in preparation to demonstrate readiness for formal clinical trials in humans. [5] On January 30, 2001, the FDA granted AbioMed an investigational device exemption (IDE) for implantation into humans via a clinical trial. [9] This opened the door for the first implantation of the AbioCor into Robert Tools on July 2, 2001. He lived for 151 days before having a fatal cerebrovascular accident. [3] [10] [11] Time magazine awarded the AbioCor its Invention of the Year award in late 2001. [11]

The second patient, Tom Christerson, who was given less than a 20 percent chance of surviving 30 days at the time of his surgery, lived for 512 days after receiving the AbioCor, dying on February 7, 2003, due to the wearing out of an internal membrane of the AbioCor. [12] An additional 12 patients had the device implanted into 2004, resulting in an average life span of less than five months among all 14 patients. In some cases the device extended survival by several months, allowing the patients to spend valuable time with family and friends. In two cases, the device extended survival by 10 and 17 months respectively, and one patient was discharged from the hospital to go home. For a patient to be eligible for implantation with the AbioCor, the person must have had severe heart failure (with failure of both ventricles) and had to be likely to die within two weeks without transplantation. [1] [2]

Though the device was initially rejected by FDA Circulatory System Devices Panel in 2005 for Humanitarian Device Exemption (HDE) status, [1] it was eventually approved by the Food and Drug Administration on September 5, 2006, for HDE status. [13] However, only one patient received the AbioCor after approval, a "76-year-old man with congestive heart failure, who did not qualify for a heart transplant." [14]

In August 2012, key AbioCor researcher and developer David Lederman died from pancreatic cancer. [15]

The company also had plans to improve the AbioCor with a second version based upon the AbioCor ventricles and the Penn State energy converter. It was expected to last for five years, more than triple the life expectancy of AbioCor. The company stated it would be 30 percent smaller than the original model, and it could be implanted in smaller men and women. Additional modifications were planned to reduce the patient's risk of stroke, which was a concern of the FDA. [10] [16] As of March 2016, AbioCor II has not come to fruition, however. Additionally, the AbioCor product has been removed from the AbioMed website, with several news agencies reporting in 2015 that the company had quietly abandoned further development of the device. [6] [7]

In 2019, Abiomed was marketing the Impella Ventricular Support Systems, left-side heart pump models "intended to help pump blood in patients who need short-term support (up to 6 days)". [17]

The AbioCor heart is featured in the 2009 film Crank: High Voltage , when it is transplanted into the main character Chev Chelios's (Jason Statham) chest after he had been abducted by Chinese mobsters in the very beginning of the movie. However, the heart depicted in the film has a much lower battery life but gives Chev superhuman athleticism when fully charged (for dramatic purposes). [18] The model of the heart in the movie is called AviCor.

See also

Related Research Articles

<span class="mw-page-title-main">William DeVries</span> American physician

William Castle DeVries is an American cardiothoracic surgeon, mainly known for the first transplant of a TAH using the Jarvik-7 model.

<span class="mw-page-title-main">Artificial cardiac pacemaker</span> Medical device

An artificial cardiac pacemaker, commonly referred to as simply a pacemaker, is an implanted medical device that generates electrical pulses delivered by electrodes to one or more of the chambers of the heart. Each pulse causes the targeted chamber(s) to contract and pump blood, thus regulating the function of the electrical conduction system of the heart.

An artificial organ is a human made organ device or tissue that is implanted or integrated into a human — interfacing with living tissue — to replace a natural organ, to duplicate or augment a specific function or functions so the patient may return to a normal life as soon as possible. The replaced function does not have to be related to life support, but it often is. For example, replacement bones and joints, such as those found in hip replacements, could also be considered artificial organs.

<span class="mw-page-title-main">Artificial heart</span> Mechanical device which replaces the heart

An artificial heart is an artificial organ device that replaces the heart. Artificial hearts are typically used to bridge the time to complete heart transplantation surgery, but research is ongoing to develop a device that could permanently replace the heart in the case that a heart transplant is unavailable or not viable. As of December 2023, there are two commercially available full artificial heart devices; in both cases, they are for temporary use, of less than a year, for total heart failure patients awaiting a human heart to be transplanted into their bodies.

<span class="mw-page-title-main">Ventricular assist device</span> Medical device to assist or replace a heart

A ventricular assist device (VAD) is an electromechanical device that provides support for cardiac pump function, which is used either to partially or to completely replace the function of a failing heart. VADs can be used in patients with acute or chronic heart failure, which can occur due to coronary artery disease, atrial fibrillation, valvular disease, and other conditions.

St. Jude Medical, Inc. was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. Its major markets include the United States, Europe, Latin America and Asia-Pacific. The company was named after Jude the Apostle, the patron saint of lost causes.

Gerson "Gus" Rosenberg is an American biomedical engineer. He is the Jane A. Fetter Professor of Surgery, professor of bioengineering, and chief of the Division of Applied Biomedical Engineering at Penn State's Milton S. Hershey Medical Center and Penn State College of Medicine.

Abiomed, Inc. is a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment. Abiomed develops and manufactures temporary external and implantable mechanical circulatory support devices. The company is headquartered in Danvers, Massachusetts with additional offices in Woburn, Baltimore, Berlin, Aachen, and Tokyo.

Adrian Kantrowitz was an American cardiac surgeon whose team performed the world's second heart transplant attempt at Maimonides Medical Center in Brooklyn, New York on December 6, 1967. The infant lived for only six hours. At a press conference afterwards, Kantrowitz emphasized that he considered the operation to have been a failure.

A wearable cardioverter defibrillator (WCD) is a non-invasive, external device for patients at risk of sudden cardiac arrest (SCA). It allows physicians time to assess their patient's arrhythmic risk and see if their ejection fraction improves before determining the next steps in patient care. It is a leased device. A summary of the device, its technology and indications was published in 2017 and reviewed by the EHRA Scientific Documents Committee.

Destination therapy is a therapy that is final rather than being a transitional stage until another therapy—thus, in transportation metaphor, a destination in itself rather than merely a bridge or road to the destination. The term usually refers to ventricular assist devices or mechanical circulatory support to keep the existing heart going, not just until a heart transplant can occur, but for the rest of the patient's life expectancy. It is thus a course of treatment for severe heart failure patients who are not likely candidates for transplant. In contrast, bridge-to-transplant therapy is a way to stay alive long enough, and stay healthy enough, to await transplant while maintaining eligibility for transplant.

Thoratec Corporation is a United States-based company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart-failure patients worldwide. It is a global leader in mechanical circulatory support devices, particularly in ventricular assist devices (VADs).

Impella is a family of medical devices used for temporary ventricular support in patients with depressed heart function. Some versions of the device can provide left heart support during other forms of mechanical circulatory support including ECMO and Centrimag.

SynCardia Systems, LLC, headquartered in Tucson, Arizona, was founded in 2001 and is the sole manufacturer and provider of the world's only clinically proven and commercially approved Total Artificial Heart.

ReliantHeart, Inc. is a privately held American company headquartered in Houston, Texas that designs, manufactures, and provides remote monitoring capabilities for its left ventricular assist devices which are used to assist circulation for failing hearts.

Berlin Heart GmbH is a German company that develops, produces and markets ventricular assist devices (VADs). The devices mechanically support the hearts of patients with end-stage heart failure. Berlin Heart's products include the implantable INCOR VAD and the paracorporeal EXCOR VAD. To date, Berlin Heart produces the only device of its kind available for babies and children with severe heart failure.

<span class="mw-page-title-main">Protected percutaneous coronary intervention</span>

Protected percutaneous coronary intervention, abbreviated as Protected PCI, is a heart procedure that involves a ventricular assist device that is used to treat patients with cardiovascular disease, including advanced heart failure.

Pump thrombosis (PT) is considered a specific case of a major device malfunction, and is classified as either suspected or confirmed pump thrombus. Typically, the device is an implanted blood pump such as a left ventricular assist device. The malfunction is a blockage in the flow of blood anywhere along a vessel and it is mainly due to the bio-incompatible presence of a fairly complex mechanical apparatus. Pump thrombus is dreaded complication of CF LVAD technology that can require repeat surgery to replace the pump or lead to death.

Jack Greene Copeland is an American cardiothoracic surgeon, who has established procedures in heart transplantation including repeat heart transplantation, the implantation of total artificial hearts (TAH) to bridge the time to heart transplant, innovations in left ventricular assist devices (LVAD) and the technique of "piggybacking" a second heart in a person, while leaving them the original.

<span class="mw-page-title-main">David Lederman</span> American aerospace engineer, entrepreneur, author, and humanitarian.

David M. Lederman was an American aerospace engineer, entrepreneur, author, and humanitarian. He is noted for founding Abiomed, the company that developed AbioCor, the first fully implantable artificial heart.

References

  1. 1 2 3 "National Medical Policy – NMP188" (PDF). HealthNet. September 2015. p. 17. Retrieved March 15, 2016.
  2. 1 2 "Medical Policy Manual – Policy No: 52" (PDF). Regence. December 2015. p. 22. Retrieved March 15, 2016.
  3. 1 2 "Heart Assist Devices – AbioCor Implantable". Texas Heart Institute. Archived from the original on March 7, 2016. Retrieved March 15, 2016.
  4. ↑ "Product Details". AbioMed. 2007. Archived from the original on May 21, 2007. Retrieved March 15, 2016.
  5. 1 2 Dowling, R.D.; Etoch, S.W.; Stevens, K.A.; Johnson, A.C.; Gray Jr., L.A. (2001). "Current status of the AbioCor implantable replacement heart". The Annals of Thoracic Surgery. 71 (3): S147–S149. doi:10.1016/S0003-4975(00)02615-1. PMID   11265850.
  6. 1 2 Leprince, P. (October 6, 2015). "Total artificial heart: What's new?" (PDF). Daily News – EACTS. European Association for Cardio-Thoracic Surgery. p. 7. Archived from the original (PDF) on March 15, 2016. Retrieved March 15, 2016.
  7. 1 2 Palomino, J. (November 4, 2015). Lopatto, E.; Zelenko, M. (eds.). "The Heart is Just a Pump: Inside the 50-year quest to build a mechanical organ". The Verge. Vox Media, Inc. Retrieved March 15, 2016.
  8. ↑ "7 Things About Artificial Hearts That You Should Know". SynCardia Systems, Inc. September 12, 2014. Retrieved March 15, 2016.
  9. ↑ Castellucci, L. (January 30, 2001). "Abiomed gets FDA approval to implant total artificial heart in humans". Medscape. Medscape, Inc. Retrieved March 15, 2016.
  10. 1 2 "Heart Replacement". AbioMed. 2007. Archived from the original on June 15, 2007. Retrieved March 15, 2016.
  11. 1 2 Hamilton, A. (November 19, 2001). "Abiocor Artificial Heart". Time – Best Inventions of 2001. Time, Inc. Retrieved March 15, 2016.
  12. ↑ "Tom Christerson, World's Second Artificial Heart Patient, Passes Away February 7, 2003". The Implantable Artificial Heart Project. February 7, 2003. Retrieved March 15, 2016.
  13. ↑ "Abiomed Receives FDA Approval of The AbioCor, The World's First Completely Self-Contained, Implantable Artificial Heart". The Implantable Artificial Heart Project. September 5, 2006. Retrieved March 15, 2016.
  14. ↑ Rothman, C. (June 24, 2009). "Surgeons perform first artificial heart implant in New Jersey". NJ.com. New Jersey On-Line, LLC. Retrieved March 15, 2016.
  15. ↑ Hevesi, D. (August 28, 2012). "David Lederman, Pioneer of Artificial Heart, Dies at 68". The New York Times. Retrieved March 15, 2016.
  16. ↑ "AbioCor: Frequently Asked Questions" (PDF). AbioMed, Inc. November 2010. p. 2. Archived from the original (PDF) on March 17, 2016. Retrieved March 15, 2016.
  17. ↑ "Impella Ventricular Support Systems – P140003/S018". Food and Drug Administration . Archived from the original on April 24, 2018.
  18. ↑ "Adrenalin 2: Visoka napetost (Crank: High Voltage)". PlanetSiol.net. TSmedia, medijske vsebine in storitve, d.o.o. August 7, 2012. Retrieved March 15, 2016.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.